Genmab is an unusual company in pharma. In 25 years, it has 44 INDs — 20 of those are still in clinical development — and eight marketed medicines. Until Wednesday’s $1.8 billion deal for antibody-drug conjugate maker ProfoundBio, it had never done a takeover.
But it’s not the drugmaker’s first go with ADCs. Genmab markets Tivdak with Pfizer, by way of the pharma giant’s acquisition of Seagen.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.